Dr. Lal Path Labs
Market cap ₹32,864 Cr
- P/E
- 56.36
- Day range
- ₹1,950.00 – ₹1,998.30
- 52-week range
- ₹1,272.60 – ₹2,079.00
- Volume
- 1.86 L
- Open
- ₹1,972.30
- Prev close
- ₹1,980.20
Latest results · Q2 FY27(consolidated)Revenue ₹874 Cr+19.6%Profit ₹194 Cr+27.4%Margin 22.2%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
LALPATHLAB in NSE indices and F&O
Research profile
Composite 66 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.8%
- Graham no.
- ₹361.49
- vs Graham
- -81.6%
- ROE ÷ P/B
- 1.8%
- 12-1 mom.
- +20.4%
- Return / vol
- 0.95
- Magic Formula
- #298
- Piotroski
- 3/6
- FCF yield
- 1.4%
Appears in 18 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Dr. Lal Path LabsLALPATHLAB | ₹32,864 Cr | 56.36 | 12.20 | 21.8% | 28.0% | 32.0% | 0.08 | +19.6% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Key metrics
- P/E (TTM)
- 55.5
- Price / Book
- 11.98
- ROE (FY26)
- 21.8%
- ROCE (latest year)
- 28%
- Dividend yield
- 0.70%
Moving averages (NSE)
- 20-day
- ₹1,939.41
- Price above
- 50-day
- ₹1,930.44
- Price above
- 200-day
- ₹1,671.96
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- FII
- Public
- Others
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 19 Dec 2025: earlier bars are per pre-bonus share.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 539 | 545 | 602 | 660 | 597 | 603 | 670 | 731 | 660 | 703 | 798 | 874 |
| Expenses | 398 | 401 | 432 | 458 | 443 | 434 | 478 | 506 | 480 | 516 | 550 | 594 |
| Operating Profit | 141 | 145 | 170 | 202 | 154 | 169 | 192 | 224 | 179 | 187 | 248 | 280 |
| OPM % | 26% | 27% | 28% | 31% | 26% | 28% | 29% | 31% | 27% | 27% | 31% | 32% |
| Other Income | 18 | 18 | 21 | 22 | 25 | 26 | 28 | 25 | -6 | 24 | 32 | 34 |
| Interest | 7 | 7 | 6 | 6 | 5 | 5 | 5 | 5 | 7 | 6 | 6 | 7 |
| Depreciation | 36 | 37 | 35 | 35 | 36 | 36 | 35 | 40 | 42 | 45 | 44 | 47 |
| Profit before tax | 116 | 120 | 150 | 183 | 138 | 153 | 181 | 204 | 124 | 160 | 229 | 260 |
| Tax % | 29% | 28% | 28% | 29% | 29% | -1% | 26% | 25% | 26% | 17% | 25% | 26% |
| Net Profit | 82 | 86 | 108 | 131 | 98 | 156 | 134 | 152 | 91 | 132 | 170 | 194 |
| EPS in Rs | ₹4.87 | ₹5.06 | ₹6.37 | ₹7.73 | ₹5.78 | ₹9.26 | ₹7.90 | ₹8.99 | ₹5.40 | ₹7.84 | ₹10.11 | ₹11.55 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
0 days since Mar 2021
-9 days since Mar 2021
-9 days since Mar 2021
-1 days since Mar 2021
-3 days since Mar 2021
Strengths, risks & growth
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]
Strengths
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 36.4%
Risks
- Stock is trading at 12.2 times its book value
- The company has delivered a poor sales growth of 11.8% over past five years.
Compounded Sales Growth
- 10 Years
- +13%
- 5 Years
- +12%
- 3 Years
- +11%
- TTM
- +17%
Compounded Profit Growth
- 10 Years
- +15%
- 5 Years
- +12%
- 3 Years
- +30%
- TTM
- +13%
Stock Price CAGR
- 10 Years
- +13%
- 5 Years
- +2%
- 3 Years
- +14%
- 1 Year
- +27%
Return on Equity
- 10 Years
- +22%
- 5 Years
- +21%
- 3 Years
- +22%
- Last Year
- +22%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 53.21% | 53.21% | 53.19% | 52.93% | -0.26 pp |
| FII | 20.29% | 17.18% | 17.35% | 18.73% | +1.38 pp |
| DII | 19.20% | 21.37% | 21.59% | 21.57% | -0.02 pp |
| Government | 0.01% | 0.01% | 0.01% | 0.00% | -0.01 pp |
| Public | 6.94% | 7.88% | 7.48% | 6.35% | -1.13 pp |
| Others | 0.35% | 0.34% | 0.38% | 0.41% | +0.03 pp |
Filed with NSE for Sept 2026: promoters 52.93%, public 46.66%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 18.76% (-0.10 pp)- Promoters53.1%
- Foreign institutions18.8%
- Mutual funds18.8%
- Insurance2.5%
- Other domestic institutions0.4%
- Retail4.0%
- Others2.4%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Flexi Cap Fund | 2.23% | 0.69% | -0.03 pp |
| UTI Flexi Cap Fund | 1.39% | 2.07% | +0.06 pp |
| Aditya Birla SL Flexi Cap Fund | 1.35% | 1.59% | +0.23 pp |
| SBI Large & Midcap Fund | 0.75% | 0.62% | +0.04 pp |
| Nippon India Small Cap Fund | 0.74% | 0.32% | +0.01 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026. Adjusted for 1 corporate action.
Risk
- Volatility (1Y)
- 28.6%
- Downside volatility
- 23.2%
- Worst 5% of days
- 2.5%
- Average of that tail
- 2.9%
- Max drawdown (1Y)
- 24.7%
- Below its peak
- 3.2%
Against the market
- Beta vs Nifty 50
- 0.38
- Correlation
- 0.18
- Relative strength (3M)
- +0.8%
- ATR (14)
- 3.3%
Return
- Return 1M
- +5.7%
- Return 3M
- +4.7%
- Return 6M
- +19.4%
- Return 1Y
- +27.2%
- vs 200-day average
- +17.6%
Momentum
- RSI (14)
- 52.3
- MACD histogram
- 3.14
- Stochastic %K
- 48.9
- ADX (14)
- 25.2
- +DI / −DI
- 20.4 / 14.0
- Money flow index
- 47.6
Participation
- Delivery (20d avg)
- 60.2%
- vs its 60-day baseline
- +3.7 pts
- Volume vs 20-day
- -0.7σ
- Close vs day's VWAP
- -0.3%
- 52-week position
- 91 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
3 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — passed
- Free cash flow
- ₹462 Cr
- FCF yield
- 1.4%
- Cash conversion
- 1.25
- Accruals ratio
- -0.040
- Net debt
- -₹120 Cr
- Net debt / equity
- -0.04
- EV / sales
- 10.79
- Capex intensity
- 6.3%
- Revenue CAGR
- 28.1%
- Profit CAGR
- 15.8%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Abhishek Maini Designated Person · ESOP | Buy | 750 | ₹8.6 L | 30 Sept 2026 |
Abhishek Maini Designated Person · Market Sale | Sell | 750 | ₹14.7 L | 30 Sept 2026 |
Munender Soperna Designated Person · ESOP | Buy | 2,100 | ₹20.3 L | 30 Sept 2026 |
Dr. Lal PathLabs Employee Welfare Trust Other · ESOP | Sell | 4,050 | ₹39.1 L | 30 Sept 2026 |
Mrinal Kapoor Designated Person · ESOP | Buy | 2,000 | ₹24.5 L | 25 Sept 2026 |
Dr. Lal PathLabs Employee Welfare Trust Other · ESOP | Sell | 3,000 | ₹36.5 L | 25 Sept 2026 |
Sanjay Kulshreshtha Designated Person · ESOP | Buy | 1,000 | ₹12.0 L | 25 Sept 2026 |
Sanjay Kulshreshtha Designated Person · Market Sale | Sell | 1,500 | ₹29.7 L | 25 Sept 2026 |
Mrinal Kapoor Designated Person · Market Sale | Sell | 2,000 | ₹39.0 L | 25 Sept 2026 |
Jai Prakash Meena Designated Person · Market Sale | Sell | 4,500 | ₹88.3 L | 21 Sept 2026 |
Sanjay Kulshreshtha Designated Person · ESOP | Buy | 1,000 | ₹14.3 L | 21 Sept 2026 |
Dr. Lal PathLabs Employee Welfare Trust Other · ESOP | Sell | 2,350 | ₹25.5 L | 21 Sept 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹5.00
Interim Dividend - Rs 5 Per Share
11 Nov 2026ex-date - dividend₹5.00
Interim Dividend - Rs 5 Per Share
30 Jul 2026ex-date - dividend₹4.00
Dividend - Rs 4 Per Share
25 Jun 2026ex-date - dividend₹3.50
Interim Dividend - Rs 3.50 Per Share
5 Feb 2026ex-date - bonusNot available — not reported in this filing
Bonus 1:1
19 Dec 2025ex-date - dividend₹7.00
Interim Dividend - Rs 7 Per Share
7 Nov 2025ex-date - dividend₹6.00
Interim Dividend - Rs 6 Per Share
6 Aug 2025ex-date - dividend₹6.00
Dividend - Rs 6 Per Share
6 Jun 2025ex-date - dividend₹6.00
Interim Dividend - Rs 6 Per Share
5 Feb 2025ex-date - dividend₹6.00
Interim Dividend - Rs 6 Per Share
5 Nov 2024ex-date - dividend₹6.00
Interim Dividend - Rs 6 Per Share
20 Aug 2024ex-date - dividend₹6.00
Dividend - Rs 6 Per Share
10 Jun 2024ex-date - dividend₹12.00
Interim Dividend - Rs 12 Per Share
13 Feb 2024ex-date - dividend₹6.00
Dividend - Rs 6 Per Share
11 Aug 2023ex-date - dividend₹6.00
Interim Dividend - Rs 6 Per Share
11 Aug 2023ex-date - dividend₹6.00
Interim Dividend - Rs 6 Per Share
5 Aug 2022ex-date - dividend₹6.00
Annual General Meeting/Dividend - Rs 6 Per Share
22 Jun 2022ex-date - dividend₹6.00
Interim Dividend - Rs 6 Per Share
18 Aug 2021ex-date - dividend₹8.00
Annual General Meeting/Dividend - Rs 8 Per Share
20 Jul 2021ex-date - dividend₹6.00
Interim Dividend - Rs 6.00 Per Share
9 Feb 2021ex-date - dividend₹6.00
Interim Dividend - Rs 6 Per Share
18 Nov 2020ex-date
Company announcements
Newspaper Publication
Attached
Attached
Attached
Attached
Attached
Attached
Attached
Attached
Attached
Attached
Attached
Attached
Attached
Attached
Filed with BSE (scrip 539524); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Jul 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
- Aug 2025TranscriptSlides
Credit ratings
- Rating update · 1 Apr from care
- Rating update · 22 Apr 2025 from care
- Rating update · 17 Mar 2025 from care
- Rating update · 14 Feb 2024 from care
- Rating update · 8 May 2023 from crisil
- Rating update · 10 Jan 2023 from care
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Dr. Lal Path Labs: common questions
Answered from the figures on this page.